Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Polyrizon Ltd.

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Receipt of Nasdaq Delisting Notice
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Ltd. Announces $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Tickers PLRZ
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
From Polyrizon Ltd.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.